DC-S239（Cat No.:I025621）is a selective small molecule inhibitor that targets the protein kinase DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A). DYRK1A plays a significant role in regulating cellular processes such as cell cycle progression, differentiation, and neuronal development. Dysregulation of DYRK1A is associated with various diseases, including Alzheimer’s disease, Down syndrome, and certain cancers. By inhibiting DYRK1A, DC-S239 has shown potential in preclinical studies to modulate disease pathways, offering a promising therapeutic approach for neurodegenerative disorders and other conditions linked to abnormal kinase activity. Its selectivity ensures fewer off-target effects.